Update on the everolimus-eluting coronary stent system: Results and implications from the SPIRIT clinical trial program

Vascular Health and Risk Management

Volumn 5, Issue , 2009, Pages 1089-1097

  Kirchner, R Michael ^a   Abbott, J Dawn ^a  

^a RHODE ISLAND HOSPITAL   (United States)

Author keywords

Cobalt chromium; Drug eluting stent; Everolimus; Percutaneous coronary intervention; Xience V

Indexed keywords

CHROMIUM; COBALT; EVEROLIMUS; PACLITAXEL; POLYMER; RAPAMYCIN; ZOTAROLIMUS;

ARTERY INTIMA PROLIFERATION; BARE METAL STENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; CORONARY STENT; DRUG EFFICACY; DRUG ELUTING STENT; DRUG SAFETY; HUMAN; IN-STENT RESTENOSIS; RANDOMIZED CONTROLLED TRIAL; REVIEW; TREATMENT OUTCOME;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; CARDIOVASCULAR AGENTS; DRUG-ELUTING STENTS; EVIDENCE-BASED MEDICINE; FEMALE; HUMANS; MALE; MULTICENTER STUDIES AS TOPIC; PROSPECTIVE STUDIES; PROSTHESIS DESIGN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; REGISTRIES; SIROLIMUS; TIME FACTORS; TREATMENT OUTCOME;

EID: 74049092736     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: None     Document Type: Review

References (28)

1. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003;349:1315-1323.
2. Stone GW, Ellis SG, Cannon L, et al. Comparison of a polymer-based paclitaxel- eluting stent with a bare metal stent in patients with complex coronary artery disease: a randomized controlled trial. JAMA. 2005;294:1215-1223.
3. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med. 2007;356:998-1008.
4. Abbott JD, Voss MR, Nakamura M, et al. Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: findings from the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol. 2007;50:2029-2036.
5. Marroquin OC, Selzer F, Mulukutla SR, et al. A comparison of baremetal and drug-eluting stents for off-label indications. N Engl J Med. 2008;358:342-352.
6. King SB 3rd, Smith SC Jr, Hirshfeld JW Jr, et al. 2007 Focused Update of the ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines: 2007 Writing Group to Review New Evidence and Update the ACC/AHA/ SCAI 2005 Guideline Update for Percutaneous Coronary Intervention, Writing on Behalf of the 2005 Writing Committee. Circulation. 2008;117:261-295.
7. Torguson R, Waksman R. Overview of the 2007 Food and Drug Administration Circulatory System Devices Panel Meeting on the Xience V Everolimus-Eluting Coronary Stent. Am J Cardiol. 2008;102:1624-1630.
8. Ding N, Pacetti SD, Tang FW, Gada M, Roorda W. XIENCE V stent design and rationale. J Interven Cardiol. 2009;22:S18-S27.
9. Waksman R, Pakala R, Baffour R, et al. Optimal dosing and duration of oral everolimus to inhibit in-stent neointimal growth in rabbit iliac arteries. Cardiovasc Revasc Med. 2006;7:179-184.
10. Grube E, Buellesfeld L. Everolimus for stent-based intracoronary applications.Rev Cardiovasc Med. 2004;5 Suppl 2:S3-S8.
11. Schuler W, Sedrani R, Cottens S, et al. SDZ RAD, a new rapamycin derivative: pharmacological properties in vitro and in vivo. Transplantation. 1997;64:36-42.
12. Serruys PW, Ong ATL, Piek JJ, et al. A randomized comparison of a durable polymer Everolimus-eluting stent with a bare metal coronary stent: The SPIRIT first trial. Eurointervention. 2005;1:58-65.
13. Tsuchida K, Piek JJ, Neumann FJ, et al. One-year results of a durable polymer everolimus-eluting stent in de novo coronary narrowings (The SPIRIT FIRST Trial). Eurointervention. 2005;1:266-272.
14. Beijk MA, Neumann FJ, Wiemer M, et al. Two-year results of a durable polymer everolimus-eluting stent in de novo coronary artery stenosis (The SPIRIT FIRST Trial). Eurointervention. 2007;3:206-212.
15. Serruys PW, Ruygrok P, Neuzner J, et al. A randomised comparison of an everolimus-eluting coronary stent with a paclitaxel-eluting coronary stent:the SPIRIT II trial. Eurointervention. 2006;2:286-294.
16. Ruygrok PN, Desaga M, Van Den Branden F, et al. One year clinical follow-up of the XIENCE V Everolimus-eluting stent system in the treatment of patients with de novo native coronary artery lesions: the SPIRIT II study. Eurointervention. 2007;3:315-320.
17. Khattab AA, Richardt G, Verin V, et al. Differentiated analysis of an everolimus- eluting stent and a paclitaxel-eluting stent among higher risk subgroups for restenosis: results from the SPIRIT II trial. Eurointervention. 2008;3:566-573.
18. Claessen BE, Beijk MA, Legrand V, et al. Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V Everolimus-Eluting Stent in the treatment of patients with de novo native coronary artery lesions: The SPIRIT II Trial. Circ Cardiovasc Intervent. 2009;2:339-347.
19. Stone GW, Midei M, Newman W, et al. Comparison of an everolimus-eluting stent and a paclitaxel-eluting stent in patients with coronary artery disease: a randomized trial. JAMA. 2008;299:1903-1913.
20. Stone GW, Midei M, Newman W, et al. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents two-year clinical follow-up from the clinical evaluation of the Xience V Everolimus Eluting Coronary Stent System in the treatment of patients with de novo native coronary artery lesions (SPIRIT) III Trial. Circulation. 2009;119:680-686.
21. Onuma Y, Serruys PW, Kukureja N, Stone GW, Spirit II, Invest III. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: pooled analysis of two-year clinical follow-up from the SPIRIT II and III trials. J Am Coll Cardiol. 2009;53:A9-A10.
22. Gordon PC, Applegate RJ, Hermiller JB, et al. Clinical and angiographic outcomes with an everolimus-eluting stent in large coronary arteries: The SPIRIT III 4.0 mm Registry. Cath Cardiovasc Int. Published online 31 Aug 2009. DOI: 1.1002/ccd.22259.
23. Shimohama T, Otake H, Ako J, et al. IVUS Analysis in the SPIRIT III Japan Treated with XIENCE V Everolimus-Eluting Stent Compared to the SPIRIT III US Arm. Am J Cardiol. 2008;102:138I.
24. Nikolsky E, Lansky AJ, Sudhir K, et al. SPIRIT IV trial design: a large-scale randomized comparison of everolimus-eluting stents and paclitaxel-eluting stents in patients with coronary artery disease. Am Heart J. 2009;158:520-526.e2.
25. Joner M, Nakazawa G, Finn AV, et al. Endothelial cell recovery between comparator polymer-based drug-eluting stents. J Am Coll Cardiol. 2008;52:333-342.
26. Onuma Y, Kukreja N, Piazza N, et al. The everolimus-eluting stent in real- world patients 6-month follow-up of the X-SEARCH (Xience V Stent Evaluated at Rotterdam Cardiac Hospital) Registry. J Am Coll Cardiol. 2009;54:269-276.
27. Biondi-Zoccai G, Lotrionte M, Moretti C, et al. Percutaneous coronary intervention with everolimus-eluting stents (Xience V): systematic review and direct-indirect comparison meta-analyses with paclitaxel-eluting stents (Taxus) and sirolimus-eluting stents (Cypher). Minerva Cardioangiol. 2008;56(1):55-65.
28. Park KW, Yoon JH, Kim JS, et al. Efficacy of Xience/promus versus Cypher in rEducing Late Loss after stENTing (EXCELLENT) trial: study design and rationale of a Korean multicenter prospective randomized trial. Am Heart J. 2009;157:811-817.e1.